Greenwich LifeSciences (GLSI) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Greenwich LifeSciences (GLSI) over the past year, gaining 75.5% versus a gain of 37.0%. Over five years, SLGL leads with a -22.8% price change compared with -59.5% for GLSI. Sol-Gel Technologies is the larger company by market cap ($230.5 million vs $217.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | SLGL |
|---|---|---|
| Share price | $14.84 | $70.40 |
| Market cap | $217.82M | $230.49M |
| 1-day change | -3.57% | -2.15% |
| YTD return | -26.75% | +70.73% |
| 1-year return | +37.04% | +75.52% |
| 5-year return | -59.46% | -22.85% |
| EPS (TTM) | $-1.53 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $97.97 |
| 52-week low | $7.78 | $28.81 |
| Distance from 52-week high | -56.48% | -28.14% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +284.10% | +116.62% |
| Average volume | 138.72K | 55.30K |
| Shares outstanding | 14.68M | 3.27M |
| Employees | — | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed GLSI by 38.5 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
GLSI vs SLGL FAQ
Which is bigger, Greenwich LifeSciences or Sol-Gel Technologies?
Sol-Gel Technologies (SLGL) is larger, with a market capitalization of $230.49M compared with $217.82M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or SLGL?
SLGL returned +75.52% over the past 12 months, compared with +37.04% for GLSI (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.